Podcasts about apellis

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

Drs. Katherine Talcott and Akshay Thomas join to discuss the March 2025 edition of Retinal Physician focusing on dry age-related macular degeneration, including photobiomodulation, complement inhibition, and deep learning for imaging.Relevant Financial Disclosures: Dr. Sridhar has consulted for Apellis.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Katherine Talcott and Yoshihiro Yonekawa join to discuss four recent publications in major ophthalmology journals.Featured articles:Anti-VEGF or PRP First for PDR (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2822892)Face Down Positioning for Macular Holes (https://www.aaojournal.org/article/S0161-6420(24)00483-4/fulltext)Management of Post-Cataract Endophthalmitis (https://www.ophthalmologyretina.org/article/S2468-6530(24)00337-3/abstract)PDS Clinical Trial Results (https://www.ophthalmologyretina.org/article/S2468-6530(24)00400-7/fulltext)ReferenceMichels Retinal Detachment (referenced in podcast, https://www.amazon.com/Retinal-Detachment-Ronald-G-Michels/dp/0801634172)Relevant Financial Disclosures: Dr. Sridhar and Dr. Talcott have consulted for Apellis and Iveric.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Various developments in the biopharma industry are discussed, including Novo's CEO being pressured to cut prices of obesity and diabetes drugs, the FTC suing major pharmacy benefit managers over insulin prices, Bluebird laying off another 25% of its workforce, and Apellis' eye drug being turned down in Europe. Large pharmaceutical companies face challenges as patent protections for their blockbuster drugs expire, forcing them to find new products and markets. Resources are provided on topics such as oncology research, AI in clinical research, overcoming clinical trial delays, and creating compelling biopharma data packages.Masimo CEO Joe Kiani resigned following a proxy battle with an activist investor, and Michelle Brennan was named as the acting CEO. Medtronic and Siemens Healthineers partnered on spine surgery, with Siemens integrating its robotic x-ray imaging system with Medtronic's spine surgery suite. Roche launched a test that can detect 12 respiratory viruses simultaneously, including influenza and COVID-19. The FDA appointed Ross Segan to lead the office responsible for premarket authorizations and recalls. A study found that only 30 out of 157 heart devices with class I recalls had undergone premarket clinical testing.The text discusses various healthcare-related news and insights for healthcare leaders on September 25, 2024. It highlights the need for more oversight in remote patient monitoring in Medicare to avoid fraud and misuse, as well as the increasing number of claims denials reported by providers. The Department of Health and Human Services is set to invest nearly $75 million in rural healthcare, focusing on expanding substance use disorder treatment and maternal healthcare services.Amgen's immune drugs for eczema and myasthenia gravis met their objectives in phase 3 trials, but results underwhelmed Wall Street. Novo's CEO was pressed by the Senate to cut prices of obesity and diabetes drugs. Struggling 2seventy scrapped a key cancer study to save money in the near term. Biogen and UCB received long-awaited lupus data. To improve cancer treatments, the nonprofit Cancer Research Institute aims to foster partnerships between scientists and the pharmaceutical industry.Merck's Keytruda combination therapy failed in a phase III colorectal cancer study, following a similar outcome for Bristol Myers Squibb in December 2023. Amgen saw late-stage wins in eczema and myasthenia gravis, with mixed results according to analysts. Novo Nordisk's CEO agreed to meet with PBMs on pricing for Ozempic and Wegovy, which are expected to dominate the next round of Medicare price negotiations in 2025. The BACE credential is recommended for those seeking to advance their biotech career.Sour Patch Kids has created a translator app to simplify corporate jargon for Gen Z entering the workforce. Mazda's new brand platform aims to enhance customer experiences and community activations. TikTok has updated its search ads with keyword targeting, while Firehouse Subs brings back its hot sauce bar with a new campaign. Coca-Cola is discontinuing its spiced flavor after just 7 months.Regeneron's Eylea empire is facing challenges as competitors launch biosimilars of the blockbuster eye drug. Sales of Eylea have decreased while Roche's drug Vabysmo has seen a significant increase in sales. Additionally, gene therapies are entering late-stage trials for wet AMD, potentially changing the treatment landscape dominated by Eylea.Novo Nordisk and Eli Lilly are investing billions in licensing and M&A deals to expand their obesity pipelines beyond GLP-1s, solidifying their dominance in the market. Regulators and policymakers are urged to create incentives to make MPoX a more attractive investment opportunity to effectively combat disease. Cancer and diabetes drugs are predicted to dominate the 2025 Medicare ne

Drs. Safa Rahmani and Kat Talcott join to discuss four recent major ophthalmology papers.Culture or No Culture for Endophthalmitis (https://ophthalmologyretina.org/article/S2468-6530(24)00338-5/abstract)Risk of Retinal Tear after Cataract Surgery (https://www.aaojournal.org/article/S0161-6420(24)00392-0/abstract)AREDS2 and GA Progression (https://www.aaojournal.org/article/S0161-6420(24)00425-1/abstract)Resident Salary and Benefits (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2820695#google_vignette)Relevant Financial Disclosures: Dr. Sridhar and Dr. Talcott have consulted for Apellis and Iveric.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Learn how real-world data (RWD) can be utilized in clinical trials to create more diverse control arms and expedite the process of bringing therapies to market. The FDA's considerations for sponsors using RWD in external control arms are essential for understanding the benefits of this approach.The Centers for Medicare and Medicaid Services (CMS) have introduced a new pathway, Transitional Coverage for Emerging Technologies, which will evaluate five medical device candidates annually for national coverage. Various acquisitions and partnerships within the healthcare industry are shaping the landscape, including Zimmer's acquisition of OrthoGrid and Abbott collaborating with Medtronic on diabetes technology.Updates in the healthcare industry encompass a range of topics, from Walgreens considering a full sale of VillageMD to the increasing uninsured rate. Leveraging technology such as AI, virtual reality, and robotics is becoming more prevalent in healthcare to enhance decision-making and patient engagement.Eli Lilly's successful quarter and Novavax's revenue miss highlight the diverse outcomes seen in the pharmaceutical industry. The merger of Recursion and Exscientia signifies a step forward in drug discovery using AI, while companies like Apellis and Madrigal continue to make strides with new drug launches.Eli Lilly's positive performance in the second quarter, along with Novavax's challenges, demonstrate the dynamic nature of the pharmaceutical market. Merck's halt of a phase III trial and Novartis' FDA approval for Fabhalta further showcase the evolving landscape of drug development and approvals.The top-selling drugs in 2024 from leading pharmaceutical companies like Eli Lilly and Roche offer insights into current trends in the industry. With a focus on diversity, commercialization strategies, and oncology research, the pharmaceutical sector continues to evolve to meet changing demands.Support the Show.

Dr. Philip Rosenfeld joins to discuss the Angiogenesis 2024 meeting, with topics covered including imaging breakthroughs for age-related macular degeneration, geographic atrophy treatment benefits and risks, and the importance of molarity in assessing efficacy and safety of intravitreal agents.Relevant Financial Disclosures: Dr. Rosenfeld has consulted for Regeneron and Zeiss. Dr. Sridhar has consulted for Apellis, Genentech, Iveric, and Regeneron.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Kat Talcott, Akshay Thomas, and Sarwar Zahid join to preview the March 2024 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: Dr. Talcott and Dr. Sridhar ha consulted for Apellis and Iveric.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Priya Vakharia and Yoshihiro Yonekawa join to discuss three recent publications in major ophthalmology journals.Ocular Adverse Events After Faricimab (https://www.ophthalmologyretina.org/article/S2468-6530(23)00644-9/fulltext)Retinal Redetachment after Cataract Surgery (https://www.ophthalmologyretina.org/article/S2468-6530(23)00581-X/fulltext)Syfovre Editorial (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2812713)Relevant Financial Disclosures: Drs. Sridhar and Vakharia have consulted for Apellis, Genentech, Iveric, and Regeneron.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

 This panel discussion on startup commercial strategy explores key elements and insights from industry leaders, Paul Bresge, Aziz Mottiwala, Todd Pinkney, Cari Stone and Adam Szaronos, offering a comprehensive view of the journey from regulatory approval to commercialization. Beth Marsh, Lead of Sales and Marketing at Apellis, sets the stage by emphasizing the importance of early consideration of commercial strategy. Key topics covered in the discussion include:Early Commercial StrategyElements of Robust StrategyRaising Institutional FundingEvolution of StrategiesFuture AnticipationDon't miss out – listen now for a comprehensive view of navigating the complexities of startup success!

Drs. Lediana Goduni, Josh Uhr, and Sarwar Zahid join to preview the January 2024 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: Dr. Sridhar has consulted for Apellis and Iveric.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Jon Denny has been a National Executive Sales and Marketing Recruiter for over 24 years in the Pharmaceutical, Biotech, Medical Devices, and Medical Diagnostics Industries with leading national recruitment firm, Buckman Enochs Coss & Associates (BEC Search). Established in 1979, BEC Search specializes in helping the best Healthcare and Life Science companies find the best people for every level of their organization, Commercial, Med Affairs, Sales, and Marketing Executives - for Projects and Retained. They have partnered with leading companies such as Allergan/Abbvie, Biodesix, Amgen, Apellis, Cardinal Health, Dompe, Genentech, Lantheus, Shionogi, Inc., Supernus Pharmaceuticals, Takeda, Travere Therapeutics, Vertos Medical, and many others.  Before joining BEC, Jon spent over two years in Accounting and Finance Recruitment for a leading staffing firm and 4 years in College/University Recruitment.  In the last two decades, Jon has helped countless individuals in healthcare sales, marketing, and clinical roles find employment opportunities that have been life-changing and he has several current clients he helped early on in their careers. Jon attributes his transformative approach to a unique blend of business acumen, strong work ethic, empathy, and ability to connect with individuals. These traits find their roots in his competitive collegiate athletic background, where he played football for four years at his alma mater, Ohio Northern University. What you'll learn in this episode: The importance of human connection in leadership and recruiting The crucial role of preparation in the recruiting process, for both the candidate and recruiter Reasons why people leave their jobs and how they often relate to issues with management or a lack of development opportunities The impact of a transformational approach in recruitment for greater success How understanding a candidate's story and motivation reveals insights into their suitability The necessity of understanding a candidate's purpose and its connection to career aspirations The high value placed on intangible qualities such as character, integrity, and work ethic in potential hires Additional Resources:  Jon's LinkedIn Jon's Twitter/X  About BEC Search's Website: www.becsearch.com LinkedIn Facebook Instagram Twitter/X Listen to Episode 86 with Jon Denny

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Inizio Biopharma is introducing patient access services called Inizio Engage, which aims to serve specialty patients suffering from rare, orphan, and other specialty diseases. This service supports a fully integrated patient experience from diagnosis through ongoing engagement and support. Patient access services address the complex barriers that patients and healthcare providers encounter, including pre-treatment diagnostics and enrollment, appropriate patient identification, global consent requirements, care coordination support, coverage determination and fulfillment, enrollment and welcome calls, prior authorization, appeals support, co-pay and patient assistance program eligibility, quick start and bridge coordination, specialty pharmacy and distribution triage, site of care and treatment logistics, transportation and lodging support, ongoing patient engagement and support, dose titration education, coping strategies, patient dialogue tools, adherence strategies, monitoring and mitigating adverse events, benefit re-verification and re-enrollment, and navigating re-entering society. All of these services are supported by the award-winning Trak360 platform. Inizio Engage aims to create a comprehensive support program that addresses the complex needs of patients surrounding access and affordability along with administration and adherence for specialty therapies.In other news stories in the medical technology industry: Analysts are skeptical about Medtronic's hypertension treatment facing challenges in reimbursement. Some analysts do not expect approval at all.3M settles combat earplug lawsuits with a $6 billion settlement.Medtronic identifies heart pump failure risk in recalled heartware hvad pump.GE Healthcare introduces software for AFib patients to speed up assessment.Boston Scientific's AFib device matches standard of care based on FARAPULSE trial data.The US signs consent decree on ethylene oxide rule.These news stories cover legal settlements, product recalls, software innovations, and regulatory issues in the medical technology industry.In biopharmaceutical news: Apellis plans to lay off 25% of its staff and scale back research activities.Catalent expands its board of directors as part of a deal with activist investor Elliott.Medicare names the first 10 drugs subject to price negotiations.Superluminal Medicines attracts investment for its drug discovery efforts targeting GPCRs.The FTC pulls back on its legal challenge to Amgen's bid for Horizon, signaling a potential settlement.Biomedevice Boston event is promoted, highlighting the opportunity to join a community of industry professionals, educational aspects, potential partnerships, networking events, and innovation in the medical device industry.The rare disease market has seen significant growth, but smaller biotech companies are struggling due to the market downturn and reduced investment in research and development. Even the oncology space is no longer a safe haven.Glassdoor releases a list of the best places to work in pharma according to employees, highlighting work-life balance. The pharma industry's migraine treatment landscape is explored.The market for cell and gene therapies continues to grow, with the FDA expected to approve up to 12 new treatments in 2023.An upcoming webinar will discuss how AI can aid in drug development, addressing challenges faced by the pharmaceutical research industry and emphasizing the urgency to take advantage of AI now.The Biden administration announces a list of top-selling prescription drugs that will be included in the first round of Medicare price negotiations.That's all for today's news in Pharma and Biotech. Stay tuned for more updates.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.MilliporeSigma has introduced its optimized VirusExpress platform for the development and manufacturing of lentiviral vectors. The platform aims to provide industry-leading titers, robust recovery, streamlined workflows, and reduced development timelines. MilliporeSigma will be showcasing its VirusExpress platform at various events.MilliporeSigma is the U.S. and Canada life science business of Merck KGaA.The FDA panel has rejected Medtronic's renal denervation device, stating that the risks outweigh the benefits. Levita has received 510(k) clearance for its surgeon-controlled arm for magnetic procedures. Draeger's ventilator sound insulation has triggered an FDA class I recall due to concentrations of a potentially carcinogenic foam component being above acceptable levels. Recor has gained FDA panel backing for its high blood pressure device, although there are concerns over the long-term durability of the treatment.Cigna has announced that it will remove prior authorizations for 25% of its services, aiming to reduce administrative burdens and streamline healthcare process for patients.CVS has launched a new venture called Cordavis, which will work directly with manufacturers to market or co-produce low-cost biologic drugs. CMS has threatened to cut hospices from Medicare if they cannot prove their legitimacy.Pharmaceutical companies are preparing for the next wave of COVID-19 infections caused by new variants of the virus. Researchers are concerned about infectious strains like "eris," which have been detected in large cities in the United States. Public health leaders and the pharmaceutical industry are working to develop and distribute vaccines to combat the new variants.Royalty Pharma has made its first gene therapy deal by buying into Ferring's cancer treatment adstiladrin for up to $500 million. Startup Cellares has raised $255 million in funding, with investors pouring cash into cell therapy production. Agenus is set to lay off 25% of its staff and trim its pipeline in a push for cancer drugs. Roche's surprise study results have spurred new optimism for TIGIT drugs.Pharmaceutical companies Pfizer, Moderna, and Novavax are preparing for the next wave of COVID-19 infections caused by new variants of the virus. Public health leaders and the pharmaceutical industry are working to develop and distribute vaccines to combat the new variants.Apellis has discovered faulty needles in its probe of a rare side effect of its eye drug, Syfovre. Boehringer has filed a lawsuit to block Medicare's new power to negotiate certain drug prices, claiming it is unconstitutional. Regeneron has rebounded after winning FDA approval for its longer-lasting vision loss drug, high-dose Eylea. Dexcom and Abbott are ramping up direct-to-consumer marketing in their fight for a larger share of the growing diabetes market. The FDA has approved Pfizer's RSV vaccine, called Abrysvo, for use in pregnancy. Blue Shield of California has dropped CVS Caremark as its pharmacy benefit manager.The FDA panel has given its support to Recor's renal denervation device for the treatment of high blood pressure.

Carolyn Majcher, OD, FAAOJoseph Allen, OD, FAAO, Diplo ABOFluoreSCENE Media Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.

Drs. Akshay Thomas, Priya Vakharia, and Sarwar Zahid join to discuss their take-aways from the 2023 ASRS Annual Meeting, including a deep dive on dry AMD pharmacotherapy, the role of the ASRS ReST committee, and keeping academic meetings for physicians.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Apellis and Iveric. Dr. Vakharia is a consultant for Apellis.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

On this week's episode of Biotech Hangout, guest Neil Kumar (CEO of BridgeBio) joins hosts Daphne Zohar, Brad Loncar, Tim Opler, Bruce Booth and Brian Skorney to discuss BridgeBio's long awaited, positive Phase 3 transthyretin amyloid cardiomyopathy (ATTR-CM) data, including the company's ups and downs and some leadership lessons along with the benefits of diversification. The hosts also cover the Acumen Pharmaceuticals and Eli Lilly positive Alzheimer's data, in addition to questions around safety for eye disease trials related to Apellis' Syfovre and Horizon Therapeutics' Tepezza. With a news heavy week, the group also discusses data integrity issues (including the Marc Tessier-Lavigne case), the impact of priority review vouchers and deals/M&A. *This episode aired on July 21, 2023*

Jane's guest today is the Emmy-Award-winning acting icon Henry Winkler, The Fonz himself! Henry, among his many accolades and accomplishments, is currently starring in the hit show Barry, and has produced and directed multiple television series. He is also a best-selling author, with his new memoir, Being Henry, due out in October. On the segment today, Henry talks about the ups and downs of his long and storied career, the one piece of advice that has been important to him throughout his life, and what inspires him in the day to day. Hear, too, about how he deals with negativity, his love of food, and his timeless tips that will make us all Better Than Before, physically, emotionally and spiritually, as well. Finally, he discusses why he has partnered with Apellis on their “GA Won't Wait” campaign for age-related macular degeneration, specifically Geographic Atrophy, the leading cause of blindness for over a million Americans.

Cedric Francois, MD, PhD, is the cofounder, CEO, and president of Apellis, the company behind Syfovre, the first FDA-approved treatment for geographic atrophy.Like many, his path to the top of a successful publicly traded pharmaceutical company did not come fast or easy. He learned the hard way not to rely on “soft commitments” when funding a new venture. He also learned that good instincts and a better bottle of wine can go a long way toward persuading angel investors to open their checkbooks.In this conversation with Firas Rahal, MD, Dr. Francois details the long and winding path that led him from curious physician-scientist to pharmaceutical industry leader. He shares the story of how Syfovre came to be, as well as the hits and misses through 17 years of fundraising.Hits include turning around his first angel investor during an impromptu follow-up meeting. Misses include needing to raise money turning the Great Recession in 2009—a time when there wasn't money to raise. He avoided bankruptcy by selling his company to Alcon later that year.He also shares how Eyetech/Pfizer's Macugen—a trailblazer in anti-VEGF therapies—inspired the science behind what would later become Apellis. Listen to the podcast today to discover:More about Dr. Francois's professional background, which took him from Belgium to Louisville, Kentucky, and from studying hand transplant surgery to developing retinal therapeutics.How Eyetech/Pfizer's Macugen inspired Dr. Francois's research into macrophages and complement inhibitors, which led him to develop products that target C3, the central protein of the complement cascade.What prompted a restart of the Phase III trial for Syfovre, the first FDA-approved treatment for geographic atrophy.The data behind how the drug's efficacy amplifies between 12 and 24 months.For physicians: what it's like to use Syfovre.How Apellis got its IPO done in November 2017, a process that included preparing S2 documents in two weeks and going on a four-day road show.How Dr. Francois secured his first angel investor, including the unconventional move that sealed the deal.His take on the potential diagnostics and other technology that could move retinal treatments forward.[Press Play]ResourcesCedric Francois, MD, PhD       https://apellis.com/people/cedric-francois-mdFiras Rahal, MD                       https://ois.net/firas-m-rahhal-mdApellis pipeline                       https://apellis.com/our-science/our-pipeline/

Henry Winkler - Health, Life, and 'Barry' The Not Old Better Show, Art of Living Interview Series Welcome to The Not Old Better Show, Art of Living interview series on radio and podcast. I'm Paul Vogelzang, and today's show is brought to you by BetterHelp, Give online therapy a try at betterhelp.com/NOB and Babbel. Language for Life. Check out Babbel at Babbel.com/NOB.  As part of our Art Of Living interview series, we have an amazing interview with actor, producer, spokesperson, and star of the new hit comedy Barry, Henry Winkler. Thank you so much for listening. We've got a great guest today in Henry Winkler,  who'll join us in just a moment. But, quickly, if you missed any episodes, last week was our 710th episode when I spoke with Smithsonian Associate Chris Thorogood about his upcoming Smithsonian Associates presentation titled Chasing Plants.  Two weeks ago, I spoke with Ralph White, who has written the excellent new book, Getting Out of Saigon.  Getting Out of Saigon is the remarkable story of a city on the eve of destruction and the colorful characters who respond differently to impending doom. It's about one man's quest to save innocent lives, not because it was ordered but because it was the right thing to do. Excellent subjects for our Not Old Better Show audience. If you missed those shows, along with any others, you can go back and check them out with my entire back catalog of shows, all free for you, there on our website, NotOld-Better.com.  You can Google Not Old Better and get everything you need about us! Our guest today is the actor, producer, spokesperson, and star of the new hit comedy Barry, Henry Winkler. Henry Winkler, who is partnering with Apellis to help older adults and their families become more aware of the symptoms of geographic atrophy (GA) - an advanced form of age-related macular degeneration (AMD) and a leading cause of blindness.  Henry's father-in-law, Ed, with whom he had a very close relationship, was diagnosed with AMD, which resulted in the loss of his vision and, ultimately, his independence. Henry watched as Ed's everyday life became more difficult, like driving his car, seeing the faces of his grandkids or even being able to see to pour himself a glass of water. Though Henry now finds himself around the same age as Ed when his vision started to decline, Henry is still active and has no plans to slow down. We'll have a wide ranging conversation with Henry Winkler about health, the Fonz, his upcoming season of Barry, and much more.  Please join me in welcoming to the Not Old Better Show on radio and podcast, Henry Winkler.  My thanks to  BetterHelp, Give online therapy a try at betterhelp.com/NOB and Babbel. Language for Life. Check out Babbel at Babbel.com/NOB. for sponsoring today's show.  My thanks to Henry Winkler for his generous time.  You can find out more about Apellis and how to help older adults and their families become more aware of the symptoms of geographic atrophy (GA) - an advanced form of age-related macular degeneration (AMD) and a leading cause of blindness in our show notes today. If you're over the age of 60 or have a loved one who is noticing changes in vision, talk to an eye doctor and go to GAwontwait.com to learn more. My thanks to you, for my The Not Old Better Show, Art of Living interview series on radio and podcast.  Please be well, be safe, and let's talk about better.  The Not Old Better Show, Art of Living interview series on radio and podcast.  Thanks, everybody, and we'll see you next week.

We discuss the use of microperimetry to assess treatment effects of anti-complement therapy (Apellis) of geographic atrophy with Dr. Nadia Waheed, Associate Professor of Ophthalmology, New England Eye Center, Tufts University School of Medicine.

Drs. Safa Rahmani, Priya Vakharia, and Sarwar Zahid join to discuss the April 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include approaches for geographic atrophy intravitreal injections, nuanced situations to decide how to use these new FDA-approved injections, antisepsis for intravitreal injections, and devices for delivery of subretinal and suprachoroidal retinal pharmacology.Relevant Financial Disclosures: Dr. Sridhar has consulted for Apellis and Eyepoint in the past 2 years.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Akshay Thomas and Priya Vakharia join to discuss the March 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include gene therapy and immunogenecity, applications in dry AMD, and optogenetics.Relevant Financial Disclosures: Dr. Sridhar has consulted for RegenxBio and Apellis in the past 2 years.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this episode, Ayesha talked about the FDA approval of Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy, a leading cause of blindness. The condition is an advanced form of dry age-related macular degeneration (AMD) for which there have been no treatment options up until this recent approval. Hear more about the drug, including some questions about its clinical benefit.Ayesha also talked about the FDA's emergency use authorization (EUA) of Lucira Health's over-the-counter (OTC) combination COVID-19 and flu diagnostic that can be administered at-home. The molecular PCR test is the first at-home combination test that can differentiate and detect the Influenza A, B and SARS-CoV-2 viruses in 30 minutes or less. The editorial team discussed the utility of the test, including settings in which they may be useful in and whether they may even be needed at all.Read the full articles here:Apellis' Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical BenefitFDA Authorizes First At-Home Combination COVID and Flu TestFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Drs. Akshay Thomas and Sarwar Zahid join to discuss the February 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com, focusing entirely on geographic atrophy.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Thomas and Dr. Zahid have no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Avni Finn, Shriji Patel, and Yoshihiro Yonekawa join to discuss silicone oil's use as tamponade during vitreoretinal surgery. Namely, indications for use, how to instill it, pearls for avoiding over or under fill, and pearls for removal.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. None of the participants have any relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

January 6, 2023. For the first Eye on the Cure episode for 2023, host Ben Shaberman highlights some of the promising clinical advancement made in therapy development over the last year. His recap includes discussions of emerging treatments from: SparingVision, Atsena Therapeutics, Alkeus, Belite, Apellis, Iveric Bio, MeiraGTx, AGTC, 4DMT, and Opus Genetics, which, after the recording of the episode, reported its acquisition of rights to gene therapies for Best disease and RP (RHO).

Drs. Safa Rahmani, Kat Talcott, and Sarwar Zahid join to discuss the January 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include the coding for geographic atrophy injections, private equity perspectives, biomarkers for diabetic retinopathy, and early worsening of diabetic retinopathy with anti-diabetic medications.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Talcott is a consultant for Genentech, Regenxbio, and Zeiss. Dr. Rahmani has received research funding from Regeneron. Dr. Zahid has no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Dr. Aaron Davis joins the program to discuss his experience transitioning from an academic pediatric endocrinologist to an industry position.Relevant Financial Disclosures: Dr. Davis is field director of medical science liasons for Apellis.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Avni Finn and Shriji Patel join to discuss big takeaways from the 2022 AAO Annual Meeting, including discussion of biosimilars, dry AMD treatments, high-dose aflibercept, and private equity influence in the retina community.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Finn is a consultant for Allergan and Genentech. Dr. Patel has no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Avni Finn and Shriji Patel join to discuss big takeaways from the 2022 AAO Annual Meeting, including discussion of biosimilars, dry AMD treatments, high-dose aflibercept, and private equity influence in the retina community.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Finn is a consultant for Allergan and Genentech. Dr. Patel has no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Dr. Akshay Thomas and Priya Vakharia join to discuss the November/December 2022 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include the future of retina clinic, diabetic automated screening, and controversies in macular degeneration management.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Thomas is a consultant for Allergan, Avesis, Bausch and Lomb, and Novartis. Dr. Vakharia is a consultant for Genentech and Bausch and Lomb.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Drs. Safa Rahmani, Katherine Talcott, and Akshay Thomas join to discuss the October 2022 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include uveitis clinical trials, diagnostic dilemmas in uveitis, floaters, and cataract surgery timing with macular hole surgery.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Apellis, DORC, Genentech, and Regeneron. Dr. Thomas is a consultant for Allergan, Avesis, Bausch and Lomb, and Novartis. Dr. Talcott is a consultant for Genentech, Regenxbio, and Zeiss. Dr. Rahmani has no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

A group of experts in AMD and geographic atrophy discussed two GA treatments in Phase III studies: Apellis's pegcetacoplan and Iveric Bio's Zimura.If approved, these therapies will potentially slow lesion growth and preserve vision in patients with GA. Because they require monthly or bimonthly injections, they may also dramatically increase workloads for already overtaxed retina specialists.David Boyer, MD, of Retina Vitreous Associates Medical Group, said they'll adapt. Somehow. Tarek Hassan, MD, partner and director of vitreoretinal training at Associated Retinal Consultants, agreed, noting the current working model will have to change. Somehow. “If we think we're helping our patients we'll figure it out,” he said.For better or worse, the rollout could be a gradual one. New-onset exudation has been observed in both pegcetacoplan and Zimura. This may spook some physicians, the panel noted, and they'll take a watch-and-wait approach. Even so, it's an exciting development for a challenging condition.Listen to the podcast today to hear our panel of retina experts discuss these and other questions related to dry AMD and GA treatment:Who are the ideal candidates for the forthcoming therapies from Iveric Bio and Apellis?How do you convince asymptomatic GA patients to initiate and continue treatment?How will artificial intelligence play a role in building a case for these therapies?Why do some patients with GA experience exudation?How do researchers determine clinical endpoints for GA? How does foveal center point involvement play a role?How do you decide on a proper treatment path?What therapies, drug delivery platforms, and/or technologies on the horizon are you excited about?[Listen to the Podcast]Speakers:David Boyer, MD - Retina Vitreous Associates Medical GroupTarek S. Hassan, MD, Professor of Ophthalmology - Oakland University William Beaumont School of Medicine / Partner and Director of Vitreoretinal Training - Associated Retinal ConsultantsErin Henry, PhD, Executive Director, Head of Ophthalmology - NGM BiopharmaceuticalsJ. Jill Hopkins, MD, SVP & Global Head, Ophthalmology Development Unit - NovartisCaroline R. Baumal, MD, Professor of Ophthalmology, Co-director of Retina Service - New England Eye Center, Tufts Medical Center

We are always told to trust the science and listen to the experts. If only our governments had listened to our guest this episode, Dr Mike Yeadon, whose credentials are impressive. His time as Vice President and Chief Scientific Officer at Pfizer along with his PhD in respiratory research should make everyone sit up and take notice of what he says. In this discussion Dr Yeadon gives an overview of where we are with this so-called ‘pandemic' and shares his view on how we have been lied to, how fear has been used to control us and how herd mentality has shut down debate and conversation. It is an honour to have Mike join Hearts of Oak to share his wisdom and insight. Please share this interview widely.   Dr. Michael Yeadon is an Allergy & Respiratory Therapeutic Area expert with over 23 years in the pharmaceutical industry. He trained as a biochemist and pharmacologist, obtaining his PhD from the University of Surrey (UK) in 1988.  Dr. Yeadon then worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, PAF, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers.  Joining Pfizer in 1995, he was responsible for the growth and portfolio delivery of the Allergy & Respiratory pipeline within the company. He was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008.  Under his leadership the research unit invented oral and inhaled NCEs which delivered multiple positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive collaborations such as with Rigel Pharmaceuticals (SYK inhibitors) and was involved in the licensing of Spiriva and acquisition of the Meridica (inhaler device) company.  Dr. Yeadon has published over 40 original research articles and now consults and partners with a number of biotechnology companies. Before working with Apellis, Dr. Yeadon was VP and Chief Scientific Officer (Allergy & Respiratory Research) with Pfizer.    Interview recorded 21.7.22  *Special thanks to Bosch Fawstin for recording our intro/outro on this podcast. Check out his art https://theboschfawstinstore.blogspot.com/ and follow him on GETTR https://gettr.com/user/BoschFawstin To sign up for our weekly email, find our social media, podcasts, video, livestream platforms and more go to  https://heartsofoak.org/find-us/  Please like, subscribe and share! 

Drs. Greg Lee, Kat Talcott, and Akshay Thomas join to discuss the May 2022 edition of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include patient and physician Perceptions of intravitreal injection therapy, retinal vein occlusion Clinical Trials, laser for diabetic retinopathy, and uveitis pearls. Relevant Financial Disclosures: Dr. Sridhar is a consultant for Genentech and Regeneron. Dr. Talcott is a consultant for Genentech, Regenxbio, and Zeiss. Dr. Thomas is a consultant for Allergan, Avesis, Bausch and Lomb, and Novartis. Dr. Lee is a consultant for Allergan, Alimera, Apellis, and Eyepoint.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

$2 billion in capital raises mostly by companies that start with the letter A. Find out more athttps://LifeScienceTodayPodcast.comStory References2seventy BioAscendisApellisArgenxAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

This accredited CME activity, led by Carlos De Castro, MD, Professor of Medicine, Duke Hematologic Malignancies Clinic, highlights the latest information about paroxysmal nocturnal hemoglobinuria (PNH) presented at ASH 2021 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients they may encounter with this rare condition.PNH is a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue.Supported by an educational grant from Apellis.To obtain CME credit, please go to https://checkrare.com/learning-center/courses/

Drs. Avni Finn and Marianeli Rodriguez join to discuss the November 2021 edition of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include artificial intelligence/deep learning applications in retina, low vision aids for patients, intraoperative OCT applications, and robotic vitreoretinal surgery. Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Dorc, Genentech, and Regeneron. Dr. Finn is a consultant for Allergan, Apellis, and Genentech. Dr. Rodriguez has no relevant disclosures. You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on a pair of pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis), which is underdoing phase 3 investigation in the DERBY and OAKS studies. 

Psychologist and writer, Sue Labar-Yohey, shares a personal story of her macular degeneration diagnosis and how writing helped her process her diagnosis and led to her connecting with others through her blogs.  Sue discusses Apellis-2 and advancing research on treatment for AMD.Support this podcast at — https://redcircle.com/mymacdlife-macular-degeneration-podcast/donations

The Complement system is an intriguing potential pathway for treating ALS. It's an essential part of the immune system – and many researchers believe its dysregulation could play a role in some cases of ALS. A class of drugs known as “complement inhibitors” seek to treat ALS by targeting certain proteins that are part of the complement system, also known as the complement cascade.  On Endpoints, we've previously discussed one complement inhibitor that's in trials as a treatment for ALS, Alexion's Ravulizimab. Today, we're looking at another potential treatment – Pegcetacoplan, a C3 inhibitor that's currently in a phase 2 trial for ALS sponsored by the company Apellis. Support the show: https://www.als.net/donate/ See omnystudio.com/listener for privacy information.

Earlier the month the U.S. Food and Drug Administration approved Apellis Pharmaceuticals Empaveli to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening condition in which the body's immune system destroys the oxygen carrying red blood cells. Like existing treatments Soliris and Ultomiris, Empaveli works to inhibit the complement system, but it is the first therapy to target the portion of this immune cascade known as C3. We spoke to Cedric Francois, co-founder and CEO of Apellis, about Empaveli, what advantages it may provide over existing therapies for PNH, and other indications the company will pursue for this medicine.

On This Episode Co-hosts Shawn Doyle and Dawn Prall begin the episode with a discussion on asking for help. Asking others for assistance can make you feel like a burden, but it's an important skill to practice. Dawn brings forth the idea of people asking for help in all type of situations, such as customer service or dealing with a broken leg. We all need assistance at times and those who are helpers often get joy from giving aid. Shawn and Dawn then exchange views on gender roles and how they affect perceptions and vulnerability in needing help.   In the next segment, Shawn interviews psychologist and writer, Sue Labar-Yohey. Sue shares a personal story of her macular degeneration diagnosis and how writing helped her process her diagnosis and led to her connecting with others through her blogs. With the assistance of Linda Moore, they created a popular Facebook group for those with MacD to connect and find educational resources. Sue goes on to share her views on why it's the best time in history to go blind. She then explains Apellis-2 and advancing research on treatment for AMD.  Shawn and Sue's interview echoes the earlier conversation regarding asking for help. Sue's top advice for those with MacD is to find acceptance and go ask for help. She reflects on acts of service as well as happiness created from supporting others. As an avid skier, cyclist, and dog-walker, Sue wants those with MacD to not be limited in their diagnosis, to find ways to be themselves, and to find gratitude in what they can do.  Next in the episode, Dawn and Shawn provide tips for living with MacD. They describe how to practice using peripheral vision and ‘ears to eyes' strategies. These suggestions are useful for any stage of vision loss.  The episode concludes with information about the omniReader® from Vispero's Bill Killroy and Mike Wood. The omniReader® is a lightweight, portable, scanning and reading device. The omniReader® has multilingual capability and you can customize the speed of the voice, the voice language, the size of the font, and the coloration of the font. The lightweight and durable product also has a handle for easy transportation.   What We Discuss in this Episode This eighth episode covers the following featured topics:  “…a lot of people that I talked to say, ‘I would like to ask for help, but I don't want to be a burden to someone else.' If I ask someone for help, let's ask you, Dawn, for help. If you help me, I'm not actually creating a burden for you. I'm actually creating joy for you because most people who are the helpers say, ‘It makes me feel good to help someone else.' Even though you're helping me, Dawn, you're actually helping yourself, because you feel good about giving back to the world or to your community or to your neighborhood, or to your friend.” (2:58)  “…I think it's hard for women to ask for help, because we're supposed to be able to do everything. But it's also difficult, and you tell me, I have lots of men in my life, happily, unhappily. But men don't like to ask for help, either because I believe that society sees it as a weakness.” (7:40)  “I mean, when I met my optometrist, when she first told me I'd have to stop driving, and that, this is only going to get worse girl. I said, ‘Well, how am I going to get anywhere?' She goes, ‘Ask.' I said, ‘I don't want to be a burden.' And she says, ‘Oh, god, no, you're not going to be a burden. One of the things that makes people happy is doing for others.'” (25:25)  “It's Apellis-2…basically, they put a shot in your eye. Don't worry, you are very, very, very numbed, at least I don't feel it. It is slow, it is taking a piece, a domino, out of the complimentary system. The more and more that they look, macular degeneration is an autoimmune problem. It's your body attacking yourself. That's part of what they call the compliment immune system. The compliment immune system is ancient. It is in all sorts of animals going all the way down to like lizards and everything. It is a chain reaction, a long series of dominoes. What they're doing is that knocking out a domino in the middle to slow down the chain reaction. Is that layman enough?” (32:18)  “This is the best time in history to be going blind. You have more opportunities; you have more help. You have more research than they've ever had before.” (42:38)  “Here's a practical tip for living with macular degeneration: learn to use your eyes more efficiently, learn to use a more peripheral part of your retina to see more clearly.” (44:49)  “This product is basically a portable scanning and reading device. This will take any text that you have and convert it to audio output. If you're looking to read a newspaper, read your mail, easily just put that underneath this unit. This unit has a built-in screen; it's got a 10-inch screen on it. If you want to see the material that you're reading, you can enlarge it. You can change the font coloration if you need high contrast, and you can also plug in your headset.” (49:30)  Quotables “Asking for help actually is part of being humble. It says that you don't know everything, and you cannot do everything, because nobody can.” – Dawn Prall  “Most people, 99.9999999% of people, if asked for help, will say, ‘Sure, what do you need?' And it's amazing.” – Shawn Doyle  “I still ride my bike. One of the farmers around here stopped me the other day and goes, ‘You know you can cross country ski over my fields if you want to.' So I'll probably go skiing this afternoon. I walk my dogs every day, or every day the weathers decent. Life is not over.” – Sue Labar-Yohey  “People think that they're giving up their lives, they're giving up their identity, but you're not, you just get it in a different way. You just work differently to try to get who you are.” – Sue Labar-Yohey  “Don't cut yourself short. Try to still be yourself as much as you possibly can. You'll find people to help you, you will.” – Sue Labar-Yohey   Recommended Resources - http://www.supportsight.org/  - http://www.mymacdlife.org/  - https://vispero.com/  - https://www.freedomscientific.com/  - https://www.freedomscientific.com/products/lowvision/omnireader/  - https://www.enhancedvision.com/  - https://us.optelec.com/  - https://www.healthyvisionassociation.com/  - https://www.novartis.com/  - https://www.centricbank.com/  - https://hinklestein.com/  - https://maculardegeneration.net/  - https://mymacularjournal.com/  - https://www.facebook.com/groups/mymacularjournal/  - https://health-union.com/  Support this podcast at — https://redcircle.com/mymacdlife-macular-degeneration-podcast/donations

Cedric Francois, MD, PhD, Co-Founder & CEO of Apellis Pharmaceuticals, gives an overview of paroxysmal nocturnal hemoglobinuria (PNH).

Drs. Mrinali Gupta and Ajay Kuriyan join for a group discussion of the April 2021 edition of Retinal Physician with a focus on macular degeneration and clinical trials.Relevant financial Disclosures: Dr. Gupta is a consultant for Allergan. Dr. Kuriyan is a consultant for Genentech, Regeneron, and Allergan and has received grant support from Genentech. Dr. Sridhar is a consultant for Regeneron and a unmasked treating physician for an Apellis trial.

Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.

Dr. Nancy Holekamp joins the program to discuss her career development, the paradigm shift in terms of management of persistent subretinal fluid in wet age-related macular degeneration, strategies for improving AMD treatment including the port-delivery system and gene therapy, and her role in founding Women in Retina (WinR).Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Dorc, Oxurion, and Regeneron. Dr. Holekamp has received consulting fees from Allergan, Acucela, Apellis, Lineage Cell Therapeutics, Clearside Biosciences, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva, and Regeneron. She is on the Speaker's Bureau for Allergan, Genentech, Novartis, Regeneron, and Spark. She performs contracted research with Genentech, Gemini, and Gyroscope and holds an intellectual property patent with Katalyst Surgical.

My guest today is Paula Pearson, Senior Director, Field Medical at Apellis and we discuss how to successfully recruit and hire MSLs virtually.   In this episode: Paula’s background  About Apellis and size of the team The changes Paula has to make once COVID hit The challenges Paula face along the way with this new process Some of the advantages of virtual interviewing How do candidates differentiate themselves in a virtual interview  What was most appealing to Paula and what behaviors that candidates should NOT do Advice to hiring managers How Paula sees the future of recruiting for the next few months and the next few years  

ay is joined by Dr. Amy Schefler, Dr. Chirag Shah, and Dr. Nathan Steinle for a panel discussion regarding how to best approach maximizing retina clinic efficiency and other issues new retina attendings in practice may encounter. You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio. Financial Disclosures: Dr. Sridhar: Consultant for Alcon, Alimera Sciences, and Thrombogenics. Dr. Schefler: Consultant for Allergan, Aura Biosciences, Castle Biosciences, Genentech, and Regeneron. Receives research support from Aura Biosciences, Castle Biosciences, Genentech, and Regeneron. Dr. Shah: Consultant for Regeneron. Receives research support from NIH, Alcon, Genentech, Novartis, Regeneron, Apellis, and Ellex. Dr. Steinle: Consultant for Apellis Pharmaceuticals, Alimera Sciences, Regeneron Pharmaceuticals, Genentech, Regenxbio, Carl Zeiss Meditec, Regenerative Patch Technologies, Novartis, and Vortex Surgery. Speaker’s Bureau for Alimera Sciences, Genentech, Regeneron Pharmaceuticals, NotalVision; and Novartis. Receives research support from Carl Zeiss Meditec, Genentech, Regeneron Pharmaceuticals, and Novartis. Investor in Vortex Surgical and Garbha Health.

Dr. Dante Pieramici of California Retina Consultants joins the show to discuss multiple topics including postoperative activity restrictions and virtual reality applications in retinal surgery. Dr. Sridhar has received fees for consulting for Alimera, Alcon, and Thrombogenics. Dr. Pieramici is a consultant for Genentech, Regeneron, Novartis, Allegro, Gemini, and Kodiac and receives research funding from Genentech, Regeneron, Novartis, Regenx Bio, Gemini, Adverum, RPE Patch, Stealth, and Apellis. You can now claim CME credits via the AAO website.

The complement system, part of the immune system, has long been used as a target for interventions in certain rare disease. Apellis Pharmaceuticals is developing therapies to treat rare blood and kidney diseases, but by targeting a different part of the complement system than available therapies do today. We spoke to Cedric Francois, co-founder, president and CEO of Apellis, about the complement system, Apellis’ approach, and why he thinks this will lead to better therapies for these rare diseases.

Cedric Francois, president and CEO, discusses his debut performance at JP Morgan in which he laid out the company’s plans for a Phase III trial of APL-2, the promising treatment for geographic atrophy. Francois shared the details of the trial, talked about going public, and shared one of the least recognized – but most important – challenges facing biopharma companies.

Cedric Francois, co-founder, CEO, and president of Apellis delivers an update on his start-up’s promising complement therapies. He also shares why he joined other Biotech CEOs and VCs in speaking against the proposed immigration restrictions.

Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling geographic atrophy and AMD.